Earnings Overview#

Bumrungrad Hospital Public Company Limited has released its earnings report for the first quarter of 2026, showing a slight improvement in both earnings per share (EPS) and revenue. The hospital achieved an EPS of $2.06, surpassing the expected $2.04, while revenue reached $6.2 billion, exceeding the forecast of $5.98 billion. However, despite these positive results, the stock price fell by 2.86% in pre-market trading, closing at $170, down from $175.

Key Highlights#

  • Earnings Per Share (EPS): $2.06, slightly above the forecast.
  • Revenue: $6.2 billion, up 1.4% year-over-year.
  • EBITDA: Increased by 5% year-over-year, indicating strong operational performance.
  • Non-Thai Patient Revenue: Grew by 4.2% year-over-year, contributing significantly to overall revenue.
  • Thai Patient Revenue: Declined by 3.6%, raising concerns among investors.

Company Performance#

Bumrungrad Hospital has shown solid earnings growth, with an EBITDA margin of around 40%. The company’s current ratio stands at 2.43, indicating strong liquidity to meet short-term obligations. The growth in revenue was primarily driven by an increase in non-Thai patient revenue, while the decline in Thai patient revenue is a point of concern. The hospital's balance sheet is strong, with more cash than debt, positioning it well for future expansion.

Market Reaction#

Despite beating earnings expectations, Bumrungrad’s stock price dropped by 2.86%. This decline may be attributed to investor worries over the decrease in Thai patient revenue and an increase in accounts receivable days, which rose to 71.7 days. Analysts suggest that the stock might be overvalued compared to its fair value estimate, contributing to the post-earnings selloff.

Future Outlook#

Looking ahead, Bumrungrad has not announced any further price increases for 2026, following a 4% hike at the start of the year to manage wage and cost inflation. The company is focused on expanding its services, including the development of the Bumrungrad Outpatient Oncology Institute and enhancing robotic surgeries. Executives emphasized the growth in non-Thai patient revenue and ongoing cost-saving measures.